Insmed (NASDAQ: INSM) CMO sells shares after option exercise filing
Rhea-AI Filing Summary
Insmed Inc.'s Chief Medical Officer, Martina Flammer, M.D., reported a series of equity transactions in company stock. On January 6, 2026, she exercised a stock option for 8,570 shares of common stock at an exercise price of $26.43 per share, converting a derivative position into directly held stock. That same day, she reported open-market sales of common stock, including 4,783 shares at a weighted average price of $173.47, 2,830 shares at $174.21, and 957 shares at $175.01.
Additional sales included 1,615 shares at $173.33 on January 6, 1,434 shares at a weighted average of $175.84 on January 7, and on January 8, 1,660 shares at a weighted average of $173.87 and 3,251 shares at $174.17. A portion of the shares sold was specifically to satisfy tax withholding obligations upon vesting of restricted stock units and related broker fees. After these transactions, she directly held 86,794 shares of Insmed common stock. All trades noted as (1) were effected under a Rule 10b5-1 trading plan adopted on February 27, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,660 | $173.87 | $289K |
| Sale | Common Stock | 3,251 | $174.17 | $566K |
| Sale | Common Stock | 1,434 | $175.84 | $252K |
| Exercise | Stock Option (right to buy) | 8,570 | $0.00 | -- |
| Exercise | Common Stock | 8,570 | $26.43 | $227K |
| Sale | Common Stock | 4,783 | $173.47 | $830K |
| Sale | Common Stock | 2,830 | $174.21 | $493K |
| Sale | Common Stock | 957 | $175.01 | $167K |
| Sale | Common Stock | 1,615 | $173.33 | $280K |
Footnotes (1)
- This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 4,783 shares sold at prices ranging from $172.89 to $173.87 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 2,830 shares sold at prices ranging from $173.92 to $174.80 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 957 shares sold at prices ranging from $174.97 to $175.12 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. This is the weighted average sales price representing 1,434 shares sold at prices ranging from $175.72 to $176.00 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 1,660 shares sold at prices ranging from $173.87 to $173.90 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
FAQ
What insider transactions did Insmed (INSM) report for its Chief Medical Officer?
Insmed’s Chief Medical Officer, Martina Flammer, M.D., reported exercising a stock option for 8,570 shares of common stock at $26.43 per share and multiple open-market sales of Insmed common stock between January 6 and January 8, 2026, at weighted average prices generally between about $173 and $176 per share.
Were the Insmed (INSM) CMO’s stock sales made under a Rule 10b5-1 trading plan?
Yes. A footnote states that the transactions marked with code M (1) and related sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
What was the nature of the Insmed stock option exercised by the CMO?
The filing shows a stock option (right to buy) covering 8,570 shares of common stock with an exercise price of $26.43 per share. The options became exercisable with 25% vesting on the first anniversary of the grant date and an additional 12.5% vesting on each six-month anniversary thereafter through the fourth anniversary.